Semaglutide 2.4mg Pen Injection is a prescription once-weekly GLP-1 receptor agonist injection containing semaglutide 2.4mg for subcutaneous administration. The 2.4mg strength is an established higher-dose semaglutide injection strength and is the recommended maintenance dose of Wegovy® for many eligible adults receiving treatment for chronic weight management. Current U.S. prescribing information lists a 2.4mg dose delivered by a single-dose prefilled pen.
Semaglutide works by activating GLP-1 receptors involved in appetite regulation, food intake and glucose metabolism. For approved weight-management indications, it is used together with a reduced-calorie diet and increased physical activity.
Semaglutide 2.4mg Pen Injection contains 2.4mg of semaglutide in a prefilled injection pen intended for subcutaneous administration.
The 2.4mg strength is specifically established for Wegovy® injection. Current U.S. prescribing information identifies 2.4mg as the recommended maintenance dosage for eligible adults using Wegovy for chronic weight management.
Semaglutide 2.4mg is generally reached through gradual dose escalation rather than being used as the initial dose.
Semaglutide is a GLP-1 receptor agonist that activates GLP-1 receptors involved in appetite, food intake and glucose regulation.
It can:
For weight-management treatment, semaglutide is prescribed alongside a reduced-calorie diet and increased physical activity.
Depending on the specific product and regulatory approval, semaglutide injection may be prescribed for:
The approved indication should always be confirmed against the specific manufacturer’s prescribing information.
Semaglutide treatment is generally titrated gradually to improve tolerability.
For Wegovy, the U.S. dosing schedule begins at 0.25mg once weekly and increases every four weeks through 0.5mg, 1mg and 1.7mg before reaching the recommended maintenance dosage of 2.4mg once weekly for many adults.
The appropriate maintenance dose may vary according to the patient’s response and tolerability. Semaglutide 2.4mg should not be used as an initial dose unless specifically directed by a qualified healthcare professional.
Wegovy® is the reference branded semaglutide injection associated with the 2.4mg maintenance strength.
A Semaglutide 2.4mg Pen manufactured by another pharmaceutical company may contain the same active ingredient and strength, but the manufacturer, formulation, injection device, packaging and regulatory authorization may differ.
Where legally authorized, commercially relevant search relationships include:
Semaglutide 2.4mg → Semaglutide 2.4mg Injection → Generic Semaglutide 2.4mg → Generic Wegovy 2.4mg → Wegovy 2.4mg Alternative
Generic Semaglutide 2.4mg refers to a semaglutide product manufactured and marketed by a company other than the reference-brand manufacturer where such generic or equivalent marketing is legally authorized.
Relevant commercial search terms include:
Ozempic® is another branded semaglutide injection, primarily approved for specific type 2 diabetes indications.
Although both Ozempic and Wegovy contain semaglutide, they are different branded products with different approved indications and dosing regimens.
The 2.4mg dose is associated with Wegovy’s approved weight-management dosing rather than standard Ozempic dosing.
Semaglutide 2.4mg Pen Injection is a prescription medicine and availability varies by country, manufacturer and regulatory authorization.
Customers searching for Semaglutide 2.4mg Pen Injection, Semaglutide 2.4mg Injection, Generic Semaglutide 2.4mg, Buy Semaglutide 2.4mg, Semaglutide 2.4mg Price, Generic Wegovy 2.4mg, Wegovy 2.4mg Alternative and related commercial terms can check availability through appropriately licensed pharmacies and pharmaceutical suppliers.
Prescription, dispensing, shipping and importation requirements differ across the USA, UK, UAE/Dubai, Australia, Singapore, Thailand, China and Russia.
Semaglutide 2.4mg Pen Injection is a prescription injectable medicine containing 2.4mg of semaglutide, a GLP-1 receptor agonist administered subcutaneously.
The 2.4mg strength is primarily associated with approved chronic weight-management treatment using semaglutide injection, depending on the specific product and country.
Yes. Semaglutide is a GLP-1 receptor agonist.
Established semaglutide products such as Wegovy are administered once weekly. The exact administration schedule should always follow the prescribing information for the specific product.
No. Established Wegovy treatment begins at a lower dose and is gradually increased. The 2.4mg strength is a higher maintenance dose for eligible patients.
Both contain semaglutide at the 2.4mg strength, but Wegovy® is a specific branded product. Another manufacturer’s semaglutide product should only be described as a generic or equivalent product where legally authorized.
No. Both contain semaglutide, but Ozempic and Wegovy are different branded products with different approved indications and dosing information. The 2.4mg strength is associated with Wegovy’s approved dosing regimen.
Semaglutide is prescription medicine. Online purchasing should be through an appropriately licensed pharmacy or pharmaceutical supplier and must comply with the laws of the destination country.
Common adverse effects may include nausea, diarrhea, vomiting, constipation and abdominal discomfort. Gastrointestinal reactions may be more noticeable during dose escalation.
Current U.S. Wegovy labeling contraindicates use in patients with a personal or family history of medullary thyroid carcinoma (MTC), patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or those with a serious hypersensitivity to semaglutide or product ingredients.
Storage requirements vary according to the specific product and pen formulation. Follow the manufacturer’s storage instructions and do not use a product that has been improperly stored or frozen.
Medical Disclaimer: This product information is provided for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Semaglutide is a prescription medicine and should only be used under the supervision of a qualified healthcare professional. Indications, dosing, contraindications, warnings, formulation, storage requirements and availability may vary by manufacturer and country. Always refer to the official prescribing information for the specific product.
Last Updated: August 23, 2026
Orders ship from our India Head Office within 1–2 business days of confirmation. We include full customs documentation — HS codes, certificates of origin, and pharmaceutical export permits.
Estimated delivery: 3–7 business days to UK. 7–10 business days to UAE, Saudi Arabia and Gulf countries. 10–15 days for USA and Asian countries.
All packages arrive in plain, unmarked brown boxes. No pharmacy name or medication details on the outside.
Semaglutide 2.4mg Pen Injection
Reviews
There are no reviews yet